Hirsutism surgery: Difference between revisions
Jump to navigation
Jump to search
Ochuko Ajari (talk | contribs) |
No edit summary |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hirsutism}} | {{Hirsutism}} | ||
{{CMG}} | {{CMG}}; {{AE}}{{Ochuko}}, {{RHN}}, {{EG}} | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for hirsutism is medical therapy. [[Surgery]] is usually reserved for patients with either [[ovarian tumor]], [[adrenal tumor]], perimenopausal or [[postmenopausal]] women with severe [[hyperandrogenism]] who are candidated for [[oophorectomy]], or [[bariatric surgery]] for severe [[obesity]]. | |||
==Surgery== | ==Surgery== | ||
{| align="right" | |||
| {{#ev:youtube|PF2LH6CuesY|500}} | |||
|} | |||
*The mainstay of treatment for hirsutism is medical therapy. [[Surgery]] is usually reserved for patients with either: | |||
**[[Ovarian tumor]]<ref name="Franks2012">{{cite journal|last1=Franks|first1=Stephen|title=The investigation and management of hirsutism|journal=Journal of Family Planning and Reproductive Health Care|volume=38|issue=3|year=2012|pages=182–186|issn=1471-1893|doi=10.1136/jfprhc-2011-100175}}</ref> | |||
**[[Adrenal tumor]]<ref name="Franks2012">{{cite journal|last1=Franks|first1=Stephen|title=The investigation and management of hirsutism|journal=Journal of Family Planning and Reproductive Health Care|volume=38|issue=3|year=2012|pages=182–186|issn=1471-1893|doi=10.1136/jfprhc-2011-100175}}</ref> | |||
**Perimenopausal or [[postmenopausal]] women with severe [[hyperandrogenism]] are candidated for [[oophorectomy]]<ref name="pmid24728167">{{cite journal| author=Souto SB, Baptista PV, Braga DC, Carvalho D| title=Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism. | journal=Arq Bras Endocrinol Metabol | year= 2014 | volume= 58 | issue= 1 | pages= 68-75 | pmid=24728167 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24728167 }} </ref><ref name="pmid20198556">{{cite journal| author=Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B et al.| title=Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. | journal=Exp Clin Endocrinol Diabetes | year= 2010 | volume= 118 | issue= 5 | pages= 291-7 | pmid=20198556 | doi=10.1055/s-0029-1225351 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20198556 }} </ref> | |||
**[[Bariatric surgery]] is an additional option for [[polycystic ovary syndrome|PCOS]] women with severe [[obesity]] or [[obesity]] with metabolic [[comorbidities]]<ref name="pmid22153789">{{cite journal |vauthors=Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K |title=Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group |journal=Fertil. Steril. |volume=97 |issue=1 |pages=28–38.e25 |year=2012 |pmid=22153789 |doi=10.1016/j.fertnstert.2011.09.024 |url=}}</ref><ref name="pmid24830595">{{cite journal |vauthors=Spritzer PM |title=Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=182–7 |year=2014 |pmid=24830595 |doi= |url=}}</ref> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
<br> | |||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
Latest revision as of 17:40, 10 October 2017
|
Hirsutism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Hirsutism surgery On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2], Rasam Hajiannasab M.D.[3], Eiman Ghaffarpasand, M.D. [4]
Overview
The mainstay of treatment for hirsutism is medical therapy. Surgery is usually reserved for patients with either ovarian tumor, adrenal tumor, perimenopausal or postmenopausal women with severe hyperandrogenism who are candidated for oophorectomy, or bariatric surgery for severe obesity.
Surgery
| PF2LH6CuesY|500}} |
- The mainstay of treatment for hirsutism is medical therapy. Surgery is usually reserved for patients with either:
- Ovarian tumor[1]
- Adrenal tumor[1]
- Perimenopausal or postmenopausal women with severe hyperandrogenism are candidated for oophorectomy[2][3]
- Bariatric surgery is an additional option for PCOS women with severe obesity or obesity with metabolic comorbidities[4][5]
References
- ↑ 1.0 1.1 Franks, Stephen (2012). "The investigation and management of hirsutism". Journal of Family Planning and Reproductive Health Care. 38 (3): 182–186. doi:10.1136/jfprhc-2011-100175. ISSN 1471-1893.
- ↑ Souto SB, Baptista PV, Braga DC, Carvalho D (2014). "Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism". Arq Bras Endocrinol Metabol. 58 (1): 68–75. PMID 24728167.
- ↑ Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B; et al. (2010). "Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature". Exp Clin Endocrinol Diabetes. 118 (5): 291–7. doi:10.1055/s-0029-1225351. PMID 20198556.
- ↑ Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K (2012). "Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group". Fertil. Steril. 97 (1): 28–38.e25. doi:10.1016/j.fertnstert.2011.09.024. PMID 22153789.
- ↑ Spritzer PM (2014). "Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances". Arq Bras Endocrinol Metabol. 58 (2): 182–7. PMID 24830595.